Abstracts tagged "etanercept"

Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
Wenlu Xiong¹, Rochella A. Ostrowski², William Adams³ and Rodney Tehrani⁴, ¹Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Rheumatology & Immunology, Loyola University Medical Center, Maywood, IL
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…
Abstract Number: 2274 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Events, Serious Infections, Uveitis, Crohn’s Disease, Colitis and Malignancies in Patients with Juvenile Idiopathic Arthritis on Continuous Treatment with Etanercept over Time: A Report from a Biologics Registry
Gerd Horneff¹, Frank Weller-Heinemann², Toni Hospach³, Prasad Oommen⁴, Gerd Ganser⁵, Johannes Peter Haas⁶, K Minden⁷ and Ariane Klein⁸, ¹Asklepios Clinic, Sankt Augustin, Germany, ²PRINTO, Genoa, Italy, ³Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁴University Duesseldorf, Duesseldorf, Germany, ⁵Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, ⁶Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁷Charité – University of Medicine Berlin, Berlin, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: To investigate changes in the risk for adverse events of special interest in juvenile idiopathic arthritis (JIA) patients treated with Etanercept documented in the…
Abstract Number: 2279 • 2017 ACR/ARHP Annual Meeting
Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya^1,2, Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova², Ksenia Isaeva², Olga Lomakina², Margarita Soloshenko² and Anna Karaseva², ¹Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ²Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The effectiveness of target use of biological medications depends on how personalized they are to fit patient’s individual parameters with juvenile idiopathic arthritis (JIA).…
Abstract Number: 2298 • 2017 ACR/ARHP Annual Meeting
Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Katherine Roshak¹, Joan M Sopczynski², Ricardo Suehiro² and Lisa Marshall¹, ¹Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ²Pfizer, Collegeville, PA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with onset before 16 years of age, that persists for at least 6 weeks, and has…
Abstract Number: 2455 • 2017 ACR/ARHP Annual Meeting
Efficacy of Etanercept in Elderly Patients with Rheumatoid Arthritis
Christopher J. Edwards¹, Katherine Roshak², Jack F Bukowski³, Ronald Pedersen⁴, Mazhar Thakur⁵, Lisa Marshall² and Heather Jones², ¹University Hospital Southampton, Southampton, United Kingdom, ²Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ³Clinical Affairs, Pfizer, Collegeville, PA, ⁴Department of Biostatistics, Pfizer, Collegeville, PA, ⁵Pfizer Ltd, Sandwich, United Kingdom
Background/Purpose: Ageing is associated with declining immune cell function and age-related comorbidities.1,2 In the US, the prevalence of rheumatoid arthritis (RA) is ~2% in individuals…
Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting
The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study
Ingrid Louw¹, Alan J. Kivitz², Tsutomu Takeuchi³, Yoshiya Tanaka⁴, Satoshi Nakashima⁵, Jennifer Hodge⁶, Hong Tang⁶, Paula O'Connor⁶ and Barbara Finck⁶, ¹Panorama Medical Centre, Cape Town, South Africa, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Keio University School of Medicine, Tokyo, Japan, ⁴School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Daiichi Sankyo, Tokyo, Japan, ⁶Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…
Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting
Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Michelle Frits¹, Gary Bradwin², Nancy A. Shadick¹, Christine Iannaccone³, Michael Weinblatt¹, Nader Rifai² and Katherine P. Liao⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Laboratory Medicine, Childrens Hospital Boston, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD). While…
Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Daniel Groth¹, Sivia Lapidus², Simona Nativ² and Maria Perez³, ¹Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ
Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…
Abstract Number: 3L • 2016 ACR/ARHP Annual Meeting
Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial
Jon T. Giles¹, Naveed Sattar², Sherine E. Gabriel³, Paul M. Ridker⁴, Steffen Gay⁵, Charles Warne⁶, David Musselman⁷, Laura Brockwell⁶, Emma Shittu⁶, Micki Klearman⁷ and Thomas Fleming⁸, ¹Columbia University, College of Physicians and Surgeons, New York, NY, ²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, MA, ⁵University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸University of Washington, Department of Biostatistics, Seattle, WA
Background/Purpose: Treatment of rheumatoid arthritis (RA) with tocilizumab (TCZ), a humanized monoclonal antibody directed against the IL-6 receptor, is associated with clinical efficacy and marked…
Abstract Number: 631 • 2016 ACR/ARHP Annual Meeting
Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Alfredomaria Lurati¹, Magda Scarpellini², Katia Angela re³, Mariagrazia Marrazza³, Daniela Mazzocchi³ and Antonella Laria⁴, ¹Fornaroli Hospital Rheumatology Unit Magenta Italy, Magenta, Italy, ²Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy, ³Fornaroli Hospital, Rheumatology Unit, MAgenta, Italy, ⁴Fornaroli Hospital, Rheumatology Unit, Magenta, Italy
Biologic free remission rate with etanercept in rheumatoid arthritis: a potential role of gender A.M. Lurati and A. Laria, D. Mazzocchi, K.A. Re, M. Marrazza,…
Abstract Number: 642 • 2016 ACR/ARHP Annual Meeting
Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis
Alan J. Kivitz^1,2, James R. O'Dell³, Tsutomu Takeuchi⁴, Yoshiya Tanaka⁵, Satoshi Nakashima⁶, Cass Kelleher⁷, Jennifer Hodge⁸, Barbara Finck⁷ and RApsody Study Group, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ³Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ⁵The First Department of Internal Medicine,, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁶Daiishi Sankyo, Shinagawa-Ku Tokyo, Japan, ⁷Clinical Science, Coherus BioSciences, Redwood City, CA, ⁸Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is in development as a proposed biosimilar of etanercept. This Phase III confirmatory, safety and efficacy study randomized and dosed 644 subjects with…
Abstract Number: 736 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis
Jieruo Gu¹, Liudan Tu², Minjing Zhao³, Zhiming Lin⁴, Zetao Liao⁵, Shuangyan Cao⁶, Qinghong Yu⁷ and Zhizhong Ye⁸, ¹Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ²The Third Hospital of Sun Yat-sen University, Guangzhou, China, ³The Third Affiliated Hospital of Sun Yat-sen University, guangzhou, China, ⁴Rheumatology, 3rd Affiliated Hospital of Sun Yat-Sen Uni, Guangzhou, China, ⁵Rheumatology, 3rd Affiliated Hoapital of Sun Yat-Sen Uni, Guangzhou, China, ⁶Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ⁷Department of Rheumatology, Fourth People’s Hospital of Shenzhen City, Xiangmi Lake branch, Guangzhou, China, ⁸Department of Rheumatology，ZhuJiang Hospital of Southern Medical University, Guangzhou, China
Background/Purpose: To compare the clinical、radiographic and magnatic resonance imaging change in active ankylosing spondylitis patients with etanercept and celecoxib alone/combined treatment，and to evaluate the effectiveness…
Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Bohdan P. Harvey¹, Chenqi Hu², Dongdong Wang², Yu Tian² and Zehra Kaymakcalan¹, ¹Global Biologics, AbbVie Bioresearch Center, Worcester, MA, ²DMPK-BA, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld^2,3, Eunice Chang⁴, Elya Papoyan⁴ and Michael S. Broder⁴, ¹Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.